Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acute myeloid leukemia by immunophenotyping, morphology, and cytochemical staining; myelodysplasia; or biphenotypic leukemia.~* Age less than or equal to 21 years at time of study entry.~* No prior therapy for this malignancy (patients with secondary AML following treatment of primary malignancy are eligible) except for one dose of intrathecal therapy.~* Negative pregnancy test~* Patient does not have Down syndrome, acute promyelocytic leukemia (APL), or juvenile myelomonocytic leukemia (JMML)~Exclusion Criteria:~* Positive pregnancy test~* Down syndrome, acute promyelocytic leukemia (APL), or juvenile myelomonocytic leukemia (JMML)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- HDAC (High-Dose Cytarabine) (Type: EXPERIMENTAL): Since limited characters are allowed in this passage, please see detailed Description for HDAC.
- LDAC (Low-Dose Cytarabine) (Type: EXPERIMENTAL): Since limited characters are allowed in this passage, please see detailed Description for LDAC.

Based on this trial design, predict the completion outcome and termination type (if applicable).